Accent is pioneering the field of epitranscriptome regulation to treat disease. Visit Site >
EcoR1 Capital LLC is a fundamental biotechnology-focused investment advisory firm. Based in San Francisco, EcoR1 evaluates and selects extraordinary biotechnology companies that are pursuing the highest quality science and demonstrate strong business fundamentals.
Like the EcoR1 restriction enzyme which helped to transform the biomedical field, EcoR1 seeks to help move medical research forward through investments into compelling biotech companies that are developing promising new solutions for untreated diseases.
We nurture lasting relationships.
We expand the possibilities of science.
We are committed to innovation.
Advancements in biotech are happening at a breakneck pace, and EcoR1 has the drive and vision to help patients with the most innovative science.
EcoR1 seeks to move medical research forward through thoughtful investments that are evaluated for scientific merit and business case.
Advancements in the biotech industry affect the lives of many. EcoR1 is committed to playing a role in finding answers for unmet medical needs.
EcoR1 identifies gutsy companies that have committed management and the potential to create value over and over again.
The EcoR1 team shepherds great drugs and great people over the peaks and valleys of drug discovery and development. Learn more about our leadership team.
FOUNDER AND PORTFOLIO MANAGER
Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, which invests in companies at all stages of research and development. With nearly twenty years of experience in biotech investing, Mr. Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners, one of the first hedge funds dedicated to the biotechnology sector. He currently serves as a Board Member for Prothena (NASDAQ: PRTA), a clinical-stage neuroscience company focused on the discovery and development of novel therapies. Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.
COO AND CCO
Ms. Marriott is the Chief Operating Officer and Chief Compliance Officer for EcoR1 Capital LLC, where she is responsible for operations, regulatory and compliance issues. Ms. Marriott has experience working across the diverse areas of civil and criminal litigation. Most recently, Ms. Marriott served as a Deputy District Attorney in Solano County, California, where she tried approximately 30 cases to a jury and 10 cases to the bench. Prior to serving as a prosecutor, Ms. Marriott practiced at Orrick, Herrington & Sutcliffe LLP in San Francisco for six years. While there, Ms. Marriott handled breach-of-contract disputes, business tort claims, public pensions, employment and appellate advocacy, as well as white-collar criminal defense. Ms. Marriott previously completed a clerkship on the federal Court of Appeals for the Tenth Circuit. Ms. Marriott holds a law degree from the University of California, Berkeley, and a Bachelor of Arts degree from Amherst College.
Mr. Perlen joined EcoR1 Capital LLC in June 2019 as Chief Financial Officer. He oversees the accounting and finance areas for the firm and funds as well as the day to day trade operations for the funds. Prior to joining Ecor1, Mr. Perlen served as Chief Financial Officer for seven years at Sheffield Asset Management, LLC, a Chicago-based long/short equity hedge fund manager. Prior to Sheffield, Mr. Perlen was a Vice President at Grosvenor Capital Management, LP, a global leader in the alternative asset industry. During his seven years at Grosvenor, Mr. Perlen managed a group dedicated to providing outsourced CFO functionality to a number of hedge fund managers and also assisted in performing operational due diligence reviews on underlying hedge funds. Prior to joining Grosvenor in 2005, Mr. Perlen was an Assistant Vice President at Bank of America, focusing on operational risk and accounting for the bank’s derivatives business. From 1997-2002, Mr. Perlen managed the operations and fund accounting at Sunrise Capital Partners, LLC, a San Diego-based hedge fund firm. Mr. Perlen received his Bachelor of Science in Finance from the University of Illinois at Urbana-Champaign in 1997.
DIRECTOR OF PARTNER RELATIONS
Ms. McWilliams joined EcoR1 Capital, LLC to oversee the firm’s partner relations. Ms. McWilliams assumed this role in May 2016 after spending six and a half years as a Managing Director of Capital Introductions at BTIG, LLC, a privately owned boutique broker dealer. AT BTIG, her responsibilities included building and maintaining institutional investor relationships in the South, MidWest, and Western US regions. Prior to BTIG, Ms. McWilliams spent two and a half years with UBS’s Prime Brokerage division in the Dallas branch. She began her career as a real estate investment analyst focused on student housing assets on collegiate campuses. Ms. McWilliams received her BBA in Finance from the McCombs Business School at the University of Texas – Austin.
Mr. Platshon joined EcoR1 Capital, LLC in October 2015 after spending a year at Aquilo Partners, a boutique life sciences investment bank. Alongside Ms. Stout, Mr. Platshon serves as an analyst and is responsible for due diligence and analysis of biotechnology companies for value-oriented investment opportunities. At Aquilo, Mr. Platshon prepared valuation materials and performed due diligence on M&A, licensing, and private placement transactions in the biotech, pharmaceutical and tools & diagnostics sector. Mr. Platshon holds a Bachelor of Science in Bioengineering from Stanford University, and was advised by Karl Deisseroth, the inventor of optogenetics and CLARITY, two breakthrough neuroscience technologies.
Caroline Stout specializes in operational and scientific analysis at EcoR1 Capital LLC. In her role as an EcoR1 Analyst, Ms. Stout informs the fund’s investment decisions by assessing clinical data and corporate insights to gain broad insights into biotechnology companies, markets and emerging science. She previously worked as an Investment Banking Analyst at Credit Suisse in New York, performing due diligence and financial valuation analysis for healthcare companies. She has experience working on a range of transactions in the healthcare and biotechnology sectors, including multi-billion dollar leveraged buyouts, initial public offerings and follow-on equity raises. Ms. Stout graduated magna cum laude from Georgetown University with a Bachelor of Arts in Economics, a Pre-Medical concentration, and Cognitive Science minor.
EXECUTIVE IN RESIDENCE
Mr. Tkachenko has over twenty years of experience in research, drug development and venture creation. Before joining EcoR1 Capital as an Executive-In-Residence, Alex was CEO of Epiodyne, a venture-backed biotech developing new medicines to address the opioid crisis. Prior to Epiodyne, Alex served as CEO of BlackThorn Therapeutics, a biotech company developing targeted medicines for neurobehavioral disorders. Before BlackThorn, Alex was President of Siluria Technologies, where he led the company through incubation, launch, team building and three rounds of financing. Alex started his industry career with Genentech. Alex has an MBA from Harvard Business School and a Ph.D. from Rutgers University, where his graduate work led to the identification of one of the first transcription factors disrupted by chromosomal translocations in cancer. Earlier, Alex served as a squad leader in the Soviet Army and completed a tour of combat duty in Afghanistan.
Mr. Lee joined EcoR1 Capital as an Analyst in April 2020. He is responsible for due diligence and analysis of biotechnology companies for value-oriented investment opportunities. Prior to joining EcoR1, Mr. Lee spent two years at Goldman Sachs in San Francisco, where he performed strategic and financial analyses related to M&A transactions and equity offerings for clients in the biotechnology sector. He graduated from Harvard University with a Bachelor of Arts in Neurobiology.
Ms. Spencer joined EcoR1 Capital, LLC as an analyst in July 2018. She is responsible for due diligence and analysis of biotechnology companies for value-oriented investment opportunities. Previously, Ms. Spencer spent two years at the University of Virginia Investment Management Company, where she performed diligence on investment managers across asset classes. She graduated from the University of Virginia with a Bachelor of Arts in Economics and a minor in History.
Mr. Zada joined EcoR1 in June 2018 as an Analyst and is responsible for due diligence and analysis of biotechnology companies for value-oriented investments. Prior to joining EcoR1, Mr. Zada was a Senior Associate at Brace Pharma Capital, a life sciences focused venture capital firm. Mr. Zada holds a Bachelor of Science degree in Biology from Virginia Tech, and a Master of Science degree in Biotechnology from Georgetown University.
Mr. Falanga joined EcoR1 Capital as an Entrepreneur-In-Residence in August of 2020 after spending years leading discovery immunology projects in Biotech and Academia. In addition to driving efforts in venture creation, he is responsible for due diligence and analysis of biotechnology companies for value-oriented investment opportunities. Prior to EcoR1, he was a Senior Scientist in Immunology at Repertoire Immune Medicine. Yves has a PhD in Immunology and Integrative Life Sciences from Virginia Commonwealth University (VCU) and completed his Postdoctoral training at the University of Massachusetts Medical School. His work focused on elucidating the functions Fyn and Lyn kinases in IgG-mediated allergic response and anaphylaxis as well as characterizing T cells in pediatric infectious diseases and oncology. Yves has a Bachelor degree in Biological sciences from Université de Rennes 1 (France) and grew up in the Democratic Republic of the Congo.
EcoR1 Capital, LLC
357 Tehama Street, Floor 3
San Francisco, CA 94103
Don't have an account with EcoR1?